Cenegermin-bkbj

(Oxervate)

Cenegermin-bkbj

Drug updated on 11/16/2023

Dosage FormDrops (eye: 0.002% (20 mcg/mL))
Drug ClassRecombinant human nerve growth factors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated for the treatment of neurotrophic keratitis.

Product Monograph / Prescribing Information

Document TitleYearSource
Oxervate (cenegermin-bkbj) Prescribing Information.2019Dompé U.S. Inc., Boston, MA

Systematic Reviews / Meta-Analyses